Skip to main content
Cytogen, Inc. logo

Cytogen, Inc. — Investor Relations & Filings

Ticker · 217330 ISIN · KR7217330000 KO Manufacturing
Open in API
Filings indexed 437 across all filing types
Latest filing 2022-03-16 Annual Report
Country KR South Korea
Listing KO 217330

About Cytogen, Inc.

https://www.cytogenlab.com/

Cytogen, Inc. is a biotechnology company specializing in liquid biopsy platforms for precision oncology. The company has developed proprietary technology for the rapid isolation and analysis of viable Circulating Tumor Cells (CTCs) from whole blood. Its core offering, the SmartBiopsy Platform, utilizes a high-density microporous chip with microfluidics and nanotechnology to capture CTCs efficiently. This non-invasive diagnostic approach is designed to support early cancer detection, treatment monitoring, and the advancement of personalized medicine for cancer patients.

Recent filings

Filing Released Lang Actions
사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Cytogen (주식회사 싸이토젠) covering the fiscal year 2021. It includes the independent auditor's report from Samil PricewaterhouseCoopers, detailed financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Statement of Cash Flows), and extensive notes to the financial statements. As it contains full audited financial statements for a specific fiscal year, it is classified as an Annual Report (10-K). FY 2021
2022-03-16 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company CytoGen. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors, and amendments to business purposes. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and request their participation/votes.
2022-03-08 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Cytogen) announcing a significant change (over 30%) in revenue or profit structure. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) to inform investors of material financial fluctuations before the final audit report is published. Since it is a specific regulatory disclosure of financial performance metrics rather than a full quarterly/annual report or a simple announcement of a report's availability, it falls under the 'Regulatory Filings' category. FY 2021
2022-03-08 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Cytogen. It contains the agenda for the meeting, including financial statement approval, board member appointments, and proposed amendments to the articles of incorporation. This type of document is sent to shareholders to provide information and request votes for the upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2022-03-08 Korean
[기재정정]주식매수선택권부여에관한신고
Remuneration Information Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically marked as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of shares and the list of recipients due to resignations. This type of disclosure regarding changes in capital structure and equity-based compensation for employees/directors is classified as a regulatory filing related to share capital changes.
2022-03-08 Korean
[기재정정]주식매수선택권부여에관한신고
Remuneration Information Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고 정정신고' (Correction Report regarding the Grant of Stock Options). It details changes to previously reported stock option grants, including adjustments to the number of shares and the list of recipients due to resignations. This type of filing is a standard corporate disclosure regarding capital structure and equity compensation, which falls under the 'Regulatory Filings' category as it is a specific administrative update to a previous filing.
2022-03-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.